AZNCF News and Press, AstraZeneca Plc From 05/11/22

COVID is not over, but the situation for the many vaccine developers late to the party (including Novavax) is unclear. There is significant ambiguity about what actual demand for the Novavax vaccine is; I don’t see ~2 billion doses as firm commitments. Gavi/COVAX was seen t...

Fisher's 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Nvidia, Intuit, Broadcom, Verizon, Uber, AMD, & Meta Platforms were increased while reducing Intel, Walmart, Walt Disney, Cisco, UnitedHealth, Starbucks & Visa this quarter. The top three positions ar...

THW is a rare healthcare fund that performed well in April 2022 as well as in past 3 months and 3 years. THW is relatively better protected from market risk due to exposure in global equity markets. THW’s stock selection is impressive, and top investments generated high pos...

After the Alexion maxi-acquisition, the company beat both revenue and EPS consensus. Premium pipelines deserve a premium valuation. 2022 guidance confirmed. For further details see: AstraZeneca: Our Next Growth Pick

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...

The following slide deck was published by AstraZeneca PLC in conjunction with this event. For further details see: AstraZeneca (AZN) Investor Presentations - Slideshow

BCRX halted enrollment in 3 trials of BCX9930 following elevated serum creatine in some patients, which indicates kidney impairment. While Orladeyo is doing very well, BCX9930 was BioCryst's pipeline future. With strong competition from Novartis and soliris biosims, BCX9930's pros...

The Financial Prophet's All-Weather Portfolio "AWP" delivered another solid quarter in Q1. Diversification, adjustments around pivotal points in the market, and effective hedging helped optimize the portfolio's returns. However, not everything worked out as well as it could have. ...

A direct comparison between 4 much discussed COVID vaccines has shown the 2 mRNA-based vaccines from BioNTech/Pfizer and Moderna as superior. Novavax’s genetically engineered protein vaccine, while effective, had a less impressive profile. Novavax is late to the party and s...

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...